Immunmoduláló terápia következtében kialakuló neutralizáló antitestek jelentosége es laboratóriumi meghatározása sclerosis multiplexben.

Translated title of the contribution: Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis

Erika Seres, L. Vécsei

Research output: Contribution to journalArticle

Abstract

Interferon-alpha, -beta, and -gamma have been used for the management of several diseases with varying clinical effects. Like many other proteins, all interferon species are potentially immunogenic, especially those produced by recombinant gene technologies. A reliable screening assay for anti-interferon-beta antibodies is suggested for patients with multiple sclerosis receiving interferon-beta therapy. Natural interferon-beta is a glycosylated 166 amino acid 25 kDa protein, recombinant interferon-beta is available for therapy as 1a and 1b products. Both preparations induce anti-interferon-beta antibodies, detectable in the serum of interferon-beta-treated patients with multiple sclerosis. The question of which assay is optimal for testing for anti-interferon-beta antibodies in interferon-beta-treated patients is unsettled. Two types of antibody assays are generally used: those measuring binding antibodies and those measuring neutralizing antibodies. The findings suggest that high titers of both binding and neutralizing antibodies reduce the clinical efficacy of interferon-beta in relapsing-remitting multiple sclerosis, which is important for the long-term efficacy of these drugs. Treatment with glatiramer acetate has also been shown to induce the development of "reactive antibodies" in patients with multiple sclerosis. This article briefly describes some of the findings concerning anti-interferon binding and neutralizing antibodies.

Original languageHungarian
Pages (from-to)156-162
Number of pages7
JournalIdeggyógyászati szemle
Volume59
Issue number5-6
Publication statusPublished - May 20 2006

Fingerprint

Immunomodulation
Interferon-beta
Neutralizing Antibodies
Multiple Sclerosis
Antibodies
Interferons
Relapsing-Remitting Multiple Sclerosis
Disease Management
Recombinant Proteins
Interferon-alpha
Therapeutics
Technology
Amino Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{09cbaaef99f74081939b1cf6458fd122,
title = "Immunmodul{\'a}l{\'o} ter{\'a}pia k{\"o}vetkezt{\'e}ben kialakul{\'o} neutraliz{\'a}l{\'o} antitestek jelentos{\'e}ge es laborat{\'o}riumi meghat{\'a}roz{\'a}sa sclerosis multiplexben.",
abstract = "Interferon-alpha, -beta, and -gamma have been used for the management of several diseases with varying clinical effects. Like many other proteins, all interferon species are potentially immunogenic, especially those produced by recombinant gene technologies. A reliable screening assay for anti-interferon-beta antibodies is suggested for patients with multiple sclerosis receiving interferon-beta therapy. Natural interferon-beta is a glycosylated 166 amino acid 25 kDa protein, recombinant interferon-beta is available for therapy as 1a and 1b products. Both preparations induce anti-interferon-beta antibodies, detectable in the serum of interferon-beta-treated patients with multiple sclerosis. The question of which assay is optimal for testing for anti-interferon-beta antibodies in interferon-beta-treated patients is unsettled. Two types of antibody assays are generally used: those measuring binding antibodies and those measuring neutralizing antibodies. The findings suggest that high titers of both binding and neutralizing antibodies reduce the clinical efficacy of interferon-beta in relapsing-remitting multiple sclerosis, which is important for the long-term efficacy of these drugs. Treatment with glatiramer acetate has also been shown to induce the development of {"}reactive antibodies{"} in patients with multiple sclerosis. This article briefly describes some of the findings concerning anti-interferon binding and neutralizing antibodies.",
author = "Erika Seres and L. V{\'e}csei",
year = "2006",
month = "5",
day = "20",
language = "Hungarian",
volume = "59",
pages = "156--162",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "5-6",

}

TY - JOUR

T1 - Immunmoduláló terápia következtében kialakuló neutralizáló antitestek jelentosége es laboratóriumi meghatározása sclerosis multiplexben.

AU - Seres, Erika

AU - Vécsei, L.

PY - 2006/5/20

Y1 - 2006/5/20

N2 - Interferon-alpha, -beta, and -gamma have been used for the management of several diseases with varying clinical effects. Like many other proteins, all interferon species are potentially immunogenic, especially those produced by recombinant gene technologies. A reliable screening assay for anti-interferon-beta antibodies is suggested for patients with multiple sclerosis receiving interferon-beta therapy. Natural interferon-beta is a glycosylated 166 amino acid 25 kDa protein, recombinant interferon-beta is available for therapy as 1a and 1b products. Both preparations induce anti-interferon-beta antibodies, detectable in the serum of interferon-beta-treated patients with multiple sclerosis. The question of which assay is optimal for testing for anti-interferon-beta antibodies in interferon-beta-treated patients is unsettled. Two types of antibody assays are generally used: those measuring binding antibodies and those measuring neutralizing antibodies. The findings suggest that high titers of both binding and neutralizing antibodies reduce the clinical efficacy of interferon-beta in relapsing-remitting multiple sclerosis, which is important for the long-term efficacy of these drugs. Treatment with glatiramer acetate has also been shown to induce the development of "reactive antibodies" in patients with multiple sclerosis. This article briefly describes some of the findings concerning anti-interferon binding and neutralizing antibodies.

AB - Interferon-alpha, -beta, and -gamma have been used for the management of several diseases with varying clinical effects. Like many other proteins, all interferon species are potentially immunogenic, especially those produced by recombinant gene technologies. A reliable screening assay for anti-interferon-beta antibodies is suggested for patients with multiple sclerosis receiving interferon-beta therapy. Natural interferon-beta is a glycosylated 166 amino acid 25 kDa protein, recombinant interferon-beta is available for therapy as 1a and 1b products. Both preparations induce anti-interferon-beta antibodies, detectable in the serum of interferon-beta-treated patients with multiple sclerosis. The question of which assay is optimal for testing for anti-interferon-beta antibodies in interferon-beta-treated patients is unsettled. Two types of antibody assays are generally used: those measuring binding antibodies and those measuring neutralizing antibodies. The findings suggest that high titers of both binding and neutralizing antibodies reduce the clinical efficacy of interferon-beta in relapsing-remitting multiple sclerosis, which is important for the long-term efficacy of these drugs. Treatment with glatiramer acetate has also been shown to induce the development of "reactive antibodies" in patients with multiple sclerosis. This article briefly describes some of the findings concerning anti-interferon binding and neutralizing antibodies.

UR - http://www.scopus.com/inward/record.url?scp=33747385003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747385003&partnerID=8YFLogxK

M3 - Article

C2 - 16786710

AN - SCOPUS:33747385003

VL - 59

SP - 156

EP - 162

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 5-6

ER -